Gilead increases enrollment target for remdesivir trial in COVID-19 patients
April 17, 2020 at 16:41 PM EDT
Gilead Sciences Inc on Friday increased enrollment target by 3,600 for a trial testing its experimental drug, remdesivir, in severe COVID-19 patients, a day after a media report said the drug was showing promise.
